FUDR与5-Fu在乳腺癌新辅助化疗中的临床观察  

Evaluation of FUDR and 5-Fu in neoadjuvant chemotherapy regimen in breast cancer

作　　者：杨胜利[1] 杨劼[1] 叶国麟[1] 古卫权[1] 潘瑞琳[1] 朱乐伟[1] 廖富毅[1] 

机构地区：[1]佛山市第一人民医院胸外乳腺外科,广东佛山528000

出　　处：《中国肿瘤临床与康复》2012年第1期73-74,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的通过FUDR代替5-Fu用于可手术乳腺癌的术前CEF新辅助化疗中,比较两种药物的疗效和副作用。方法 90例Ⅱ期和Ⅲ期乳腺癌患者分为两组,实验组采用含FUDR的CEF方案术前新辅助化疗,对照组采用含5-Fu的CEF方案术前新辅助化疗.结果实验组CR 2例、PR 25例,RR为60.0%。对照组CR 3例、PR 22例,RR为55.6%。实验组总有效率与对照组无明显差异(P>0.05)。实验组恶心呕吐、骨髓抑制发生率均低于对照组(P<0.05),而脱发和便秘的发生率两组无明显差异(P>0.05)。结论 FUDR代替5-Fu用于乳腺癌的CEF新辅助化疗方案是一个很好的选择。Objective To compare the efficacy and toxicity of FUDR and 5-Fu in CEF regimens as neoadjuvant chemotherapy for breast cancer. Methods Ninety patients with stage 11, III breast cancer were randomly divided into two groups, experimental group received FUDR in CEF regimen every 3 weeks, and control group received 5-Fu in CEF regimen every 3 weeks, all groups for 2 or 4 cycles of neoadjuvant chemotherapy. Results In experimental group,2 patients was complete remission （CR）, 25 patients was partial remission,and total effective rate （RR） was 60. 0%. In control group, 3 patients was complete remission （CR）, 22 patients was partial remission, and total effective rate （RR）was55.6%. There was not significant difference between the two groups （ P 〉 0. 05 ）. The side effects, including nausea, vomiting, marrow depression, the experimental group was lower than the control group （ P 〈 0. 05 ）, alopecia and costive were similar in the two groups （ P 〉 0. 05 ）. Conclusions 5-Fu insteaded by FUDR in CEF regimen as neoadjuvant chemotherapy for breast cancer is a good choice.

关 键 词：乳腺癌 新辅助化疗 FUDR CEF方案 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]